Mariner
RGLS

Mariner’s Regulus Therapeutics RGLS Stock Holding History

Mariner’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-130
Closed -$3K – 884
2018
Q3 		$3K Hold
130
– – ﹤0.01% 806
2018
Q2 		$10K Hold
130
– – ﹤0.01% 785
2018
Q1 		$11K Sell
130
-182
-58% -$24.4K ﹤0.01% 639
2017
Q4 		$39K Hold
312
– – ﹤0.01% 569
2017
Q3 		$47K Hold
312
– – ﹤0.01% 499
2017
Q2 		$37K Hold
312
– – ﹤0.01% 496
2017
Q1 		$62K Buy
312
+142
+84% +$27K ﹤0.01% 579
2016
Q4 		$46K Buy
170
+45
+36% +$14.6K ﹤0.01% 552
2016
Q3 		$50K Buy
+125
New +$51.4K ﹤0.01% 648

Other funds holding RGLS

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Mariner's RGLS Position: Q4 2018 in Review

Mariner sold out of Regulus Therapeutics (RGLS) in Q4 2018, closing a stake of 130 shares — an estimated $3K sold.

Mariner first reported a position in RGLS in Q3 2016 and held it in 9 quarters. The position peaked at $62K in Q1 2017. 27 funds tracked by Wall St. Rank hold RGLS as of Q4 2018.

  • Mariner reported no remaining Regulus Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Mariner sold 130 Regulus Therapeutics shares in Q4 2018, an estimated $3K.
  • Mariner first reported a position in Regulus Therapeutics in Q3 2016 and held it in 9 quarters.
  • Mariner's Regulus Therapeutics position peaked at $62K in Q1 2017.
  • 27 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2018.

Based on Mariner's 13F filing for Q4 2018, filed 13 Feb 2019.